```html

Fitzpatrick Skin Phototype (Photo‑Sensitivity)

Overview

The Fitzpatrick skin phototype system is a classification that predicts how a person’s skin reacts to ultraviolet (UV) radiation. Developed in 1975 by Harvard dermatologist Thomas B. Fitzpatrick, the scale ranges from Type I (very fair, always burns, never tans) to Type VI (deeply pigmented, never burns). While the classification itself is not a disease, certain phototypes are strongly linked to photo‑sensitivity—an abnormal or exaggerated skin response to sunlight.

Who it affects: All ethnicities can be placed on the Fitzpatrick scale, but the prevalence of heightened photo‑sensitivity differs:

• Type I–II (fair skin, blue or green eyes, red/blonde hair): ~10‑15 % of the U.S. population; higher risk of sunburn and phototoxic drug reactions.
• Type III–IV (medium to olive skin): ~45 % of the U.S. population; may tan but still experience burning with intense exposure.
• Type V–VI (brown to black skin): ~35‑40 % of the global population; lower risk of acute burning but can develop chronic photo‑damage such as hyperpigmentation and skin cancer.

Photo‑sensitivity is more common in people with underlying genetic conditions (e.g., xeroderma pigmentosum) or who take photosensitizing medications, regardless of phototype. Understanding one’s Fitzpatrick type helps clinicians tailor sun‑protection advice and select appropriate therapies.

Symptoms

Photo‑sensitivity manifests as an abnormal skin reaction after UV exposure. The severity and appearance depend on the underlying cause and the individual’s phototype.

Acute Symptoms (appear within minutes to hours)

• Sunburn (erythema): Red, painful patches that may swell or form blisters.
• Pruritus: Itching that can be severe, especially in conditions like polymorphous light eruption (PLE).
• Urticaria (hives): Raised, wheal‑like lesions that appear quickly after sun exposure.
• Edema: Swelling of the face, lips or extremities (seen in drug‑induced photosensitivity).
• Vesiculation: Small fluid‑filled blisters that may coalesce into larger bullae.
• Dermal erythema multiforme: Target‑shaped lesions that can affect mucous membranes.

Sub‑Acute Symptoms (days to weeks after exposure)

• Hyperpigmentation: Darker patches (post‑inflammatory hyperpigmentation) that may last months.
• Hypopigmentation: Lightened spots, particularly after severe blistering.
• Scaling / desquamation: Peeling skin as the epidermis regenerates.
• Photosensitive rashes: Eczematous or papular eruptions that persist for weeks.

Chronic / Long‑Term Findings

• Actinic keratoses: Rough, scaly plaques that can progress to squamous cell carcinoma.
• Premature skin aging (photo‑aging): Wrinkles, loss of elasticity, telangiectasias.
• Increased skin cancer risk: Basal cell carcinoma, squamous cell carcinoma, and melanoma are more common in highly photosensitive individuals.
• Photodistributed lupus erythematosus: Red, scaly lesions confined to sun‑exposed areas.

Causes and Risk Factors

Photo‑sensitivity is not a single disease; it results from a spectrum of genetic, environmental, and iatrogenic factors.

Genetic / Inherited Disorders

• Xeroderma pigmentosum (XP): Defective nucleotide excision repair leads to extreme UV sensitivity; cancer risk > 10,000‑fold.
• Porphyrias (e.g., erythropoietic, hepatic): Accumulation of photosensitizing porphyrins causes burning and swelling.
• Polymorphous light eruption (PLE) familial forms: Autosomal dominant inheritance.
• Ataxia‑telangiectasia: Impaired DNA repair, increased sun sensitivity.

Medication‑Induced Photo‑Sensitivity

Numerous drugs act as photosensitizers:

• Antibiotics: tetracyclines, fluoroquinolones, sulfonamides.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): naproxen, ibuprofen (rare).
• Antihistamines: first‑generation (e.g., diphenhydramine).
• Antifungals: voriconazole.
• Cardiovascular agents: amiodarone, thiazides.
• Retinoids and certain chemotherapeutic agents.

Autoimmune / Inflammatory Diseases

• Lupus erythematosus (systemic or cutaneous)
• Dermatomyositis
• Polymorphous light eruption
• Horseshoe‑shaped erythema (hydroa vacciniforme)

Environmental & Lifestyle Factors

• High‑altitude or equatorial residence (greater UV index).
• Outdoor occupations (construction, agriculture, lifeguarding).
• Use of tanning beds.
• Insufficient sunscreen use or improper application.

Risk Related to Fitzpatrick Phototype

• Types I–II: Higher acute burn risk; more likely to develop PLE, lupus photosensitivity, and sun‑induced skin cancer.
• Types V–VI: Lower acute burn risk but higher propensity for pigmentary changes, actinic keratoses, and melanoma in the setting of chronic exposure.

Diagnosis

Diagnosis combines a thorough history, physical examination, and often targeted tests.

Clinical Evaluation

• History: Onset of symptoms after sun exposure, drug list, family history of photosensitivity disorders, occupational exposure.
• Phototype Assessment: Determined by eye, hair, and skin color, plus tanning/burning tendency.
• Physical Exam: Distribution of lesions (typically sun‑exposed areas), morphology, presence of blistering, and chronic changes.

Phototesting

Standardized UV exposure using a handheld phototherapy unit:

• Minimal Erythema Dose (MED): The smallest UV dose that causes erythema after 24 h—lower MED indicates higher photosensitivity.
• Photoprovocation: Repeated low‑dose UV to reproduce lesions (useful for PLE, lupus).

Laboratory Tests

• Complete blood count and liver/kidney panels (to rule out drug toxicity).
• Autoimmune serology: ANA, anti‑dsDNA, anti‑Ro/La for lupus.
• Porphyrin analysis: urine, blood, and stool porphyrin levels for porphyria.
• Genetic testing for XP, ataxia‑telangiectasia, or familial PLE when indicated.

Skin Biopsy

Performed when the diagnosis is unclear; histology can differentiate phototoxic from photoallergic reactions and identify lupus or dermatomyositis-specific changes.

Imaging (Rare)

In severe cases of porphyria, abdominal imaging may be required to assess hepatic involvement.

Treatment Options

Treatment is individualized based on the underlying cause, severity, and phototype.

General Photoprotection (First‑Line for All)

• Sunscreen: Broad‑spectrum SPF 30–50+, applied 15–30 min before exposure and reapplied every 2 h.
• Protective clothing: UPF‑rated shirts, wide‑brim hats, sunglasses.
• Shade seeking: Avoid peak UV hours (10 am–4 pm).

Medication Adjustments

• Discontinue or substitute known photosensitizing drugs when possible.
• Consult prescribing physician before stopping any medication.

Topical Therapies

• Corticosteroids: Low‑to‑mid potency creams for acute inflammation (e.g., triamcinolone 0.1%).
• Calcineurin inhibitors: Tacrolimus 0.03% for steroid‑sparing in chronic eruptions.
• Vitamin C or E serums: Antioxidant adjuncts to reduce oxidative UV damage.

Systemic Therapies

• Antimalarials (hydroxychloroquine): First‑line for lupus‑related photosensitivity.
• Immunosuppressants: Azathioprine or methotrexate for refractory dermatomyositis or severe PLE.
• Antioxidants: Oral nicotinamide (500 mg BID) shown to reduce actinic keratoses in high‑risk populations (Mayo Clinic, 2020).
• Phototherapy (PUVA) for PLE: Paradoxically, controlled exposure can lead to desensitization over time.

Procedural Options

• Laser therapy (e.g., IPL): May improve persistent hyperpigmentation after photosensitive episodes.
• Cryotherapy or excision: For actinic keratoses or early skin cancers.
• Desensitization protocols: Gradual UV exposure under medical supervision for selected PLE patients.

Supportive Care

• Cool compresses & analgesics (acetaminophen) for sunburn pain.
• Hydration and moisturizers to aid barrier repair.

Living with Fitzpatrick Skin Phototype (Photo‑Sensitivity)

Practical everyday strategies empower patients to control symptoms and lower long‑term risk.

Sun‑Protection Routine

1. Apply sunscreen at least 15 minutes before stepping outdoors; use 1 oz (a shot glass) for the whole body.
2. Reapply after swimming, sweating, or every 80 minutes during prolonged exposure.
3. Choose mineral‑based sunscreens (zinc oxide, titanium dioxide) if prone to chemical irritant reactions.
4. Wear UPF 50+ clothing, especially during outdoor work or recreation.
5. Use a broad‑brimmed hat (minimum 3‑inch brim) and UV‑blocking sunglasses (ANSI Z80.3 rated).

Medication Management

• Keep an up‑to‑date list of all prescription, over‑the‑counter, and herbal products.
• Ask pharmacists to flag photosensitizing agents.
• If a photosensitizing drug is essential, plan outdoor activities for early morning or late afternoon and increase sunscreen protection.

Skin‑Care Practices

• Gentle, fragrance‑free cleansers; avoid alcohol‑based toners.
• Moisturize daily with ceramide‑rich creams to strengthen the barrier.
• Use topical antioxidants (e.g., 10 % vitamin C serum) in the morning.

Monitoring & Follow‑Up

• Perform a monthly self‑skin exam; photograph any new or changing lesions.
• Schedule dermatologist visits every 6‑12 months, or sooner if new lesions appear.
• Maintain a UV‑index diary (many weather apps display daily UV index).

Lifestyle Adjustments

• Plan outdoor activities for low‑UV times; use shade structures when possible.
• Consider vitamin D supplementation (500–1000 IU daily) if strict sun avoidance reduces levels; check serum 25‑OH‑vitamin D.
• Adopt a diet rich in antioxidants (berries, leafy greens, nuts) to support skin health.

Prevention

Preventing photo‑sensitivity complications focuses on minimizing UV exposure and optimizing skin health.

• UV‑index awareness: Keep UV index <3 when possible; use sunscreen even on cloudy days (up to 80 % of UV rays penetrate clouds).
• Environmental controls: Install UV‑filtering window film at home and in vehicles.
• Education: Teach family members, especially children, proper sunscreen application and reapplication.
• Medication review: Annual medication reconciliation with a pharmacist to identify new photosensitizers.
• Vaccination: For patients with porphyria, avoid triggers such as hepatitis C infection; vaccination can reduce risk.

Complications

If photo‑sensitivity is unmanaged, acute and chronic complications may arise:

• Severe sunburn: Can lead to dehydration, secondary infection, and intense pain.
• Photo‑allergic dermatitis: Chronic eczematous rash that may become resistant to topical steroids.
• Pigmentary disorders: Permanent hyper‑ or hypopigmentation causing cosmetic distress.
• Premature skin aging: Loss of elasticity, deep wrinkles, and telangiectasias.
• Skin cancer: Actinic keratoses, basal cell carcinoma, squamous cell carcinoma, and melanoma—risk increases 2–5‑fold in high‑risk phototypes (CDC, 2022).
• Systemic involvement: In porphyrias, acute neurovisceral attacks can be life‑threatening; in lupus, photosensitivity may herald flares involving kidneys, joints, or CNS.

When to Seek Emergency Care

---

References:

1. Fitzpatrick TB. The validity and practicality of skin phototype classification. J Invest Dermatol. 1975;55(4):102‑110.
2. Mayo Clinic. Nicotinamide for skin cancer prevention. 2020. mayoclinic.org
3. CDC. Sun safety and skin cancer prevention. 2022. cdc.gov
4. NIH – National Institute of Arthritis and Musculoskeletal and Skin Diseases. Photosensitivity disorders. 2023. niams.nih.gov
5. American Academy of Dermatology. Guidelines for photoprotection. 2021. aad.org
6. World Health Organization. Ultraviolet radiation and health. 2022. who.int

```